Literature DB >> 27136185

The Hidradenitis suppurativa patient journey in Italy: current status, unmet needs and opportunities.

V Bettoli1, S Pasquinucci2, S Caracciolo3, D Piccolo4,5, S Cazzaniga6, F Fantini7, L Binello8, G Pintori9, L Naldi10,11.   

Abstract

BACKGROUND: Hidradenitis suppurativa (HS) is a chronic, progressive inflammatory, debilitating, follicular disease of the skin with a reported incidence of less than 1% in the general population. Diagnosis of HS may typically be delayed for years, and even when diagnosed, is challenging to treat. Thus, HS has considerable negative impact on patient quality of life.
OBJECTIVES: To describe the HS patient journey in Italy, identify unmet needs and provide a proposal for integrated patient care.
METHODS: A multidisciplinary panel of leading Italian experts met to evaluate routine clinical practice and patient experience, and analyse the available scientific evidence on HS.
RESULTS: A comprehensive map of the journey of the HS patient in Italy was built based on integrated data obtained from clinical practice and patient experience. The journey is non-linear and can be grouped into four broad stages that are somewhat overlapping and intersecting: (i) onset to diagnosis; (ii) circle of visits; (iii) circle of treatments; (iv) living with HS. Several unmet needs were identified that included greater awareness of disease by both healthcare practitioners and patients.
CONCLUSION: Improved disease awareness can be addressed through continuing medical education for physicians and development of educational materials for patients, in addition to greater utilization of social networks. Moreover, the development of integrated treatment centres was considered a worthwhile goal, and would offer patients the possibility to receive multidisciplinary care, ideally with dermatologists coordinating treatment, along with surgeons, psychologists, endocrinologists, gastroenterologists, pain specialists, gynaecologists and paediatricians as needed. Lastly, standardized management protocols for HS are also needed.
© 2016 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2016        PMID: 27136185     DOI: 10.1111/jdv.13687

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  5 in total

1.  Family physicians' role in hidradenitis suppurativa management.

Authors:  Valerio De Vita
Journal:  Can Fam Physician       Date:  2017-05       Impact factor: 3.275

Review 2.  Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review.

Authors:  Nicolò Scuderi; Ambra Monfrecola; Luca Andrea Dessy; Gabriella Fabbrocini; Matteo Megna; Giuseppe Monfrecola
Journal:  Skin Appendage Disord       Date:  2017-03-21

3.  Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study.

Authors:  Miriam Calao; Jodie L Wilson; Lynda Spelman; Laurent Billot; Diana Rubel; Alan D Watts; Gregor B E Jemec
Journal:  PLoS One       Date:  2018-07-24       Impact factor: 3.240

4.  A Dermatological Questionnaire for General Practitioners with a Focus on Hidradenitis Suppurativa.

Authors:  Claudio Marasca; Maria Carmela Annunziata; Sara Cacciapuoti; Mariateresa Cantelli; Fabrizio Martora; Silvestro Scotti; Luigi Sparano; Gabriella Fabbrocini
Journal:  Open Access Maced J Med Sci       Date:  2018-10-03

5.  Identifying Unmet Care Needs and Important Treatment Attributes in the Management of Hidradenitis Suppurativa: A Qualitative Interview Study.

Authors:  Damon Willems; Mickael Hiligsmann; Hessel H van der Zee; Christopher J Sayed; Silvia M A A Evers
Journal:  Patient       Date:  2021-08-09       Impact factor: 3.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.